In a specific strain of rats with diabetes, a 7-day course of an SGLT2 inhibitor enhances how well skeletal muscle responds to insulin by lowering fat buildup inside muscle cells and increasing...

We analyzed one study on Zucker diabetic fatty rats and found that a 7-day course of an SGLT2 inhibitor was associated with improved insulin sensitivity in skeletal muscle. This improvement was linked to a reduction in triglycerides inside muscle cells and an increase in glucose uptake when insulin and glucose levels were high. The effect was specific to muscle tissue — the study did not observe changes in how the liver responded to insulin [1]. What we’ve found so far is limited to a single assertion based on one set of experimental conditions in a specific strain of rats bred to develop diabetes. The evidence we’ve reviewed leans toward the idea that, in this model, SGLT2 inhibitors may help muscle cells take up more glucose by clearing out excess fat. However, this does not mean the same happens in humans, or even in other rat models. We have no data on long-term effects, different doses, or whether these changes lead to better blood sugar control over time. The study was conducted under controlled lab conditions using high insulin and glucose levels, which may not reflect real-world metabolic states. We also have no information on whether the reduction in muscle fat was the direct cause of improved glucose uptake, or if other factors were involved. At this point, our analysis is based on one observation in one animal model. We cannot say whether this mechanism applies broadly, or if it translates to people with diabetes. More studies would be needed to understand how consistent this effect is, and whether it holds under different conditions. For now, if you’re considering SGLT2 inhibitors for metabolic health, this rat study suggests one possible way they might affect muscle metabolism — but it’s just one piece of a much larger puzzle.